Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | TK2 | O00142 | 1/20 | 0.59 |
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21316832 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887786 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL5982137 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2922785 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887635 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL13030268 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL535679 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL535680 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL15457036 | 0.90 | TK1 (0.75) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL12883747 | 0.90 | TK1 (0.75) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4651942-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | PHARMASSET, INC. (US) | 2010-07-01 | — | — | US | claimed |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | PHARMASSET, INC. (US) | 2007-08-23 | — | — | US | claimed |
| EP-1569658-A4 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | PHARMASSETT LTD (BB) | 2007-05-30 | — | — | EP | claimed |
| JP-2005528334-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1569658-A2 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | Pharmassett Ltd. (BB) | 2005-09-07 | — | — | EP | claimed |
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | EMORY UNIVERSITY | 2003-09-18 | — | — | US | claimed |
| WO-2003053360-A2 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | PHARMASSETT LTD. (BB) | 2003-07-03 | — | — | WO | claimed |
| CN-110036018-B | Nucleoside derivative or salt thereof, polynucleotide synthesis reagent, polynucleotide, and method for producing bound nucleic acid molecule | 日本电气方案创新株式会社 | 2022-09-27 | — | — | CN | disclosed |
| CN-114645051-A | Secretory immunoglobulin A (sIgA) binding nucleic acid molecule, sensor for sIgA analysis, and sIgA analysis method | 日本电气方案创新株式会社 | 2022-06-21 | — | — | CN | disclosed |
| CN-109715807-B | Secretory immunoglobulin A (sIgA) -binding nucleic acid molecule, sensor for sIgA analysis, and sIgA analysis method | 日本电气方案创新株式会社 | 2022-05-17 | — | — | CN | disclosed |
| CN-109715644-B | Nucleoside derivative or salt thereof, polynucleotide synthesis reagent, polynucleotide production method, polynucleotide, and bound nucleic acid molecule production method | 日本电气方案创新株式会社 | 2022-03-22 | — | — | CN | disclosed |
| EP-3904365-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2021-11-03 | — | — | EP | disclosed |
| EP-3401407-B1 | NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE | DNAFORM KK (JP) | 2020-04-22 | — | — | EP | disclosed |
| EP-2130835-A1 | COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID | Riken (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080227104-A1 | Replication; hybridization; kits | RIKEN (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1970453-A2 | Primer, primer set, and nucleic acid amplification method and mutation detection method using the same | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-20060142238-A1 | Chemical compounds | NuCana plc (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1646639-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | University College Cardiff Consultants, Ltd. (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005012327-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | UMPS, UNG, TYMP | TK1 5/4885CYP1A2 3476/4885CYP3A4 1565/4885 |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | UMPS, ENTPD5, TK1 | TK1 3/4885CYP1A2 2865/4885CYP3A4 1310/4885 |
| US-20080227104-A1 | Replication; hybridization; kits | PCNA, POLL, RNGTT | TK1 300/4885CYP1A2 4851/4885CYP3A4 4220/4885 |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | UMPS, ENTPD5, TK1 | TK1 3/4885CYP1A2 2865/4885CYP3A4 1310/4885 |
| US-20060142238-A1 | Chemical compounds | NUDT1, DCK, PNP | TK1 10/4885CYP1A2 3861/4885CYP3A4 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.